Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma by Ulrich-Pur, H et al.
Irinotecan plus raltitrexed vs raltitrexed alone in patients with
gemcitabine-pretreated advanced pancreatic adenocarcinoma
H Ulrich-Pur
1, M Raderer
1, GV Kornek
1, B Schu ¨ll
1, K Schmid
1, K Haider
2, W Kwasny
2, D Depisch
2,
B Schneeweiss
3, F Lang
4 and W Scheithauer*
,1
1Division of Clinical Oncology, Department of Internal Medicine I, University Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria;
2Department
of Surgery, Wr.Neustadt General Hospital, Corvinusring 3-5, A-2700 Wr.Neustadt, Austria;
3Department of Internal Medicine, Kirchdorf General Hospital,
Hausmanningerstrasse 8, A-4560 Kirchdorf a.d.Krems, Austria;
4Department of Surgery, Neunkirchen General Hospital, Peischingerstrasse 19, A.2024
Neunkirchen, Austria
There is no established second-line treatment for advanced pancreatic cancer after gemcitabine failure. In view of the urgent need for
such therapy, and since preclinical and phase I clinical data suggest an encouraging, potentially synergistic activity between raltitrexed
and irinotecan, the present randomised phase II study was initiated. A total of 38 patients with metastatic pancreatic adenocarcinoma,
who progressed while receiving or within 6 months after discontinuation of palliative first-line chemotherapy with gemcitabine, were
enrolled in this study. They were randomised to 3-weekly courses of raltitrexed 3mgm
 2 on day 1 (arm A) or irinotecan
200mgm
 2 on day 1 plus raltitrexed 3mgm
 2 on day 2 (arm B). The primary study end point was objective response, secondary
end points included progression-free survival (PFS) and overall survival (OS), as well as clinical benefit response in symptomatic
patients (n¼28). In the combination arm, the IRC-confirmed objective response rate was 16% (three out of 19 patients had a partial
remission; 95% CI, 3–40%), which was clearly superior to that in the comparator/control arm with raltitrexed alone, in which no
response was obtained. Therefore, the trial was already stopped at the first stage of accrual. Also, the secondary study end points,
median PFS (2.5 vs 4.0 months), OS (4.3 vs 6.5 months), and clinical benefit response (8 vs 29%) were superior in the combination
arm. The objective and subjective benefits of raltitrexed+irinotecan were not negated by severe, clinically relevant treatment-related
toxicities: gastrointestinal symptoms (42 vs 68%), partial alopecia (0 vs 42%), and cholinergic syndrome (0 vs 21%) were more
commonly noted in arm B; however, grade 3 adverse events occurred in only three patients in both treatment groups. Our data
indicate that combined raltitrexed+irinotecan seems to be an effective salvage regimen in patients with gemcitabine-pretreated
pancreatic cancer. The superior response activity, PFS and OS (when compared to raltitrexed), as well as its tolerability and ease of
administration suggest that future trials with this combination are warranted.
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Pancreatic adenocarcinoma, which is responsible for approxi-
mately 5% of all cancer-related deaths in the Western world
(Parker et al, 1996), continues to be a major unresolved health-care
problem. The large majority of patients present with disease that is
beyond the scope of surgical cure, and their clinical course is
characterised by debilitating symptoms and an extremely poor
prognosis (Schnall et al, 1996). Although it has been reported that
5-fluorouracil (FU)-based chemotherapy is superior than best
supportive care alone (Palmer et al, 1994; Glimelius et al, 1996),
and that gemcitabine even offers a survival advantage over FU
combined with an increased level of palliation as evidenced by
clinical end points of pain intensity, analgesic use, and perfor-
mance status (Burris et al, 1997), overall therapeutic results are
still disappointing: in the latter study, apart from the fact that FU
was used in a suboptimal way, that is, a single weekly short-term
infusion rather than a continuous infusional schedule with or
without leucovorin, the reported objective response rate in the
‘winner arm’ was only 5%. Similarly, there was only a modest
survival advantage (5.6 vs 4.4 months), and only one out of four
patients (24%) experienced clinical benefit (Burris et al, 1997).
Therefore, a number of clinical research efforts are currently being
undertaken in order to enhance the therapeutic effectiveness of
front-line chemotherapy in advanced disease, including modifica-
tion of the administration schedule of gemcitabine (Temporo et al,
1999), dose intensification (Ulrich-Pur et al, 2000), and/or its
combination with other drugs and biologicals (Heinemann, 2002).
Despite encouraging phase I/II study results, however, definitive
superior treatment results are still eagerly awaited.
An additional problem in the therapeutic management of this
common malignant disease constitutes the need for effective
treatment alternatives in patients failing gemcitabine-based
chemotherapy. Based on previous data suggesting some activity
of the topoisomerase I inhibitor irinotecan in this treatment setting
(Klapdor and Fenner, 2000), and in vitro (Aschele et al, 1998) and
in vivo evidence (Ford et al, 2000; Stevenson et al, 2001) of a
schedule-dependent synergy with the quinazoline antifolate
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lraltitrexed, a potent and selective inhibitor of thymidilate synthase
(Van Cutsem et al, 2002), the present study was undertaken. The
aim of this randomised multicentre phase II study was to
investigate the feasibility and therapeutic index of combined
irinotecan plus raltitrexed vs raltitrexed alone in patients with
advanced pancreatic adenocarcinoma, who had failed or recurred
after prior palliative gemcitabine-based first-line chemotherapy.
PATIENTS AND METHODS
Patients selection
Patients with histologically confirmed metastatic pancreatic
adenocarcinoma and bidimensionally measurable disease (defined
as presence of at least one index lesion capable of two-dimensional
measurement by computed tomography (CT) scan outside any
irradiated zone and X2cm in diameter) were considered
candidates for this study. All patients must have developed
progressive disease (PD) while receiving or within 6 months after
discontinuing palliative gemcitabine-based chemotherapy. An
interval of at least 4 weeks with full resolution of all toxicities
had to elapse before administration of the study medication.
Eligibility criteria also included a Karnofsky performance index of
at least 50%, age between 19 and 75 years, adequate bone marrow
reserve (leukocyte count X4000ml
 1,p l a t e l e tc o u n tX100000ml
 1),
adequate renal function (serum creatinine concentration
o132mmol), and adequate hepatic function (serum bilirubin level
o34mmoll
 1 and serum transaminase level o two times the
upper limits of normal). Patients may not have received more than
one palliative gemcitabine-based chemotherapy regimen and/or
extensive prior radiation therapy of more than 20% of the bone
marrow. Patients who received radiation therapy with a target
lesion outside the radiation port were allowed to participate.
Similarly, adjuvant chemo- and/or radiotherapy were acceptable.
Exclusion criteria included the presence of CNS metastases, serious
or uncontrolled concurrent medical illness, and a history of other
malignancies, with the exception of excised cervical or basal skin/
squamous cell carcinoma. Informed consent according to institu-
tional regulations was obtained from all patients before study
entry.
RANDOMISATION PROCEDURES
Before randomisation, patient eligibility was confirmed by a
protocol-specific check list. After signing informed consent
documents, and a 2–7-day pain stabilisation lead-in period in
symptomatic patients (that aimed to provide adequate pain control
and to establish base-line measures for clinical benefit response
assessment), patients were stratified according to Karnofsky
performance score (90–100 vs 50–80%), and prior response to
gemcitabine first-line chemotherapy (Complete remission (CR),
partial remission (PR), stable disease (SD) vs progression).
Patients were then assigned to one treatment regimen by the
central office located at the University in Vienna.
Treatment protocol
In both treatment arms, an identical conventional dose regimen of
raltitrexed (3mgm
 2 given as a 15-min intravenous (i.v.) infusion
on day 1) was used. In the combination arm B, according to the
described schedule-dependent synergy (Aschele et al, 1998), the
thymidilate synthase inhibitor was given on day 2, 24h after
irinotecan. Based on the results of a small disease-oriented phase I
investigation in patients with advanced pancreatic cancer (un-
published data), a lower dose of the latter drug (200mgm
 2) was
administered as recommended (350mgm
 2) in two previously
published phase I studies in other solid tumours (Ford et al, 2000;
Stevenson et al, 2001). In both treatment arms, courses were
repeated every 3 weeks for a total of six courses unless there was
prior evidence of PD. Concomitant medications routinely given
before cytotoxic drug administration included ondansetron 8mg
(plus dexamethasone 8mg in patients randomised to arm B). If
severe cholinergic symptoms were observed during or after
irinotecan infusion, 0.25mg of atropine given as a subcutaneous
injection was recommended and prophylactically administered
during subsequent courses. Specific guidelines for treatment of
delayed diarrhoea were provided, which recommended 2mg of
loperamide every 2h until more than 12h had passed after the last
loose stool.
Toxicity and dosage modification guidelines
Adverse reactions were evaluated according to World Health
Organization (WHO) criteria (Miller et al, 1981). Chemotherapeu-
tic drug doses were reduced by 25% in case of grade 4
haematotoxicity and/or if any other severe (XWHO grade 3)
organ toxicity was observed in the previous cycle. Treatment could
be delayed for up to 2 weeks until adverse effects resolved or at
least improved to grade 1. Any patient who required more than 2
weeks for recovery of adverse reactions was taken off the study.
Pretreatment and follow-up evaluation
Before chemotherapy was initiated, all patients were assessed by
physical examination, routine haematology and biochemistry
analyses, chest X-ray, and CT scans to define the extent of the
disease. Complete blood cell counts with platelet and differential
counts were obtained weekly during chemotherapy, and serum
chemistry analyses were repeated at least once every course.
Subjective symptoms, physical examination results, adverse
reactions, performance status, and other clinical benefit response
parameters were recorded before each treatment cycle. Objective
tumour reassessments were performed every 2 months.
Study objectives
The primary efficacy end point was objective response rate, which
was assessed every 2 months using WHO standard criteria. In case
of PR or CR, a second assessment 4 weeks later was required for
confirmation of response. All tumour measurements were
reviewed and confirmed by an independent panel of oncologists
and radiologists (IRC).
Secondary efficacy end points included PFS and OS time, as well
as clinical benefit response in symptomatic patients, which was
evaluated as previously described (Burris et al, 1997).
Statistical methods
The Simon (1989) two-stage optimal design was used to determine
the number of patients in this phase II study. With a 5% alpha risk
and a 15% beta risk, we determined a first-stage response
probability of 5% (which if true, implied discontinuing the trial)
and a minimal rate of efficacy of 15% (which if true, implied
moving on to the second stage of the trial). The number of patients
to be included in each arm was calculated to be 19 for the first
stage and an additional 35 for the second stage. After the inclusion
of 54 patients in each arm, the observation of four or fewer patients
with objective responses allowed a conclusion of insufficient
treatment efficacy. Differences in distribution of patients between
the two arms of the trial were evaluated with a w
2 test (Cochran,
1954). The exact binominal confidence interval was applied to
estimate the response rates. Progression-free survival and OS were
examined with the Kaplan–Meier product-limit method (Kaplan
and Meier, 1958).
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Patients’ characteristics
Between July 2000 and September 2001, a total of 38 patients were
entered onto this trial from four different institutions: 19 patients
on both treatment arms, all of whom were considered evaluable for
response and toxicity assessment. The trial was already stopped at
the end of the first stage of accrual because of the response rates
achieved. Table 1 lists demographic data, baseline disease
characteristics, and prior therapeutic interventions for all rando-
mised patients. Apart from a higher proportion of female subjects
in the raltitrexed arm, the two groups were well balanced. Most
patients were elderly, and the large majority had multiple intra-
abdominal sites of metastases. In both groups, 21–26% of patients
had undergone prior potential curative surgery with disease
recurrence after a median of 6–8 months. Four (arm A) vs six
patients (arm B) had undergone palliative surgery for biliary and/
or gastric decompression, and five patients each had received
endoscopic stents for relieving obstructive jaundice before study
entry. Palliative first-line treatment with gemcitabine monotherapy
was effected in all patients in both treatment arms, and has
resulted in abrogation of PD (PR, SD) in 58%. A total of 12 patients
(63%) in the raltitrexed group, and 14 (74%) in the combination
arm were suffering from disease-related symptoms at study entry
and were considered evaluable for clinical benefit response. In
most of these patients, pain was the predominant symptom: 11
(92%) on raltitrexed and 12 (86%) on raltitrexed+irinotecan had a
baseline pain intensity score greater than 20 points, and more than
90% in each group required more than 10 morphine-equivalent mg
day
 1 for control of pain. Similarly, most patients had an impaired
performance status at study entry. A Karnofsky performance score
of 50–80% was recorded in 15 patients (79%) in both treatment
arms. More than two-thirds of the patients had experienced weight
loss, ranging from 10 to 43% of premorbid body weight.
Treatment summary
Of the 38 patients enrolled, all received at least one dose of the
allocated treatment, almost two-thirds completed 12 weeks of
therapy, and 26% (three in arm A and seven in arm B) completed
the planned treatment period of 24 weeks. Treatment was stopped
early in only one patient in the raltitrexed + irinotecan
combination arm for adverse reactions; in all other patients the
reason for treatment discontinuation was PD. Both treatment
groups adhered closely to the planned dosage regimens. For
patients treated with raltitrexed alone, the mean duration of
treatment was 11 weeks, and for those treated with raltitrexed+
irinotecan, the mean duration of treatment was 14 weeks.
Antitumour efficacy
According to the IRC assessment, there was no objective response
in arm A, and three responses occurred in arm B for a total
response rate of 16% (95% CI, 3–40%). All responses in the
combination arm were partial, occurred within 3 months of
therapy, and lasted for a duration of 4, 5, and 7.5 months,
respectively. The study was therefore closed, and arm B was
declared ‘the winner’ according to our study design.
Disease stabilisation was noted in seven (37%) vs six (32%)
additional patients in arm A and B for a median duration of 4
(range, 3.2–6) months vs 5 (range, 4.2–9) months, respectively. At
the time of this analysis, all patients had experienced PD. The
median PFS time was 2.5 (range, 1.5–6.0) months for patients in
the raltitrexed group and 4.0 (range, 1.5–10.0) months in the
combination group. Also in terms of median survival, which was
4.3 (range, 1.8–11.0) months in arm A vs 6.5 (range, 1.5–14.0+)
months in arm B, a clear benefit was noted in favour of arm B
(Figure 1).
Clinical benefit response
In total, 28 patients with tumour-related symptoms (pain and/or
impaired performance status7weight loss) were considered
Table 1 Patients’ characteristics
Raltitrexed Raltitrexed+irinotecan
Number of patients 19 19
Gender
Male 8 12
Female 11 7
Median age in years (range) 60 (40–74) 63 (49–75)
Karnofsky performance status (%)
90–100 4 (21%) 4 (21%)
70–80 10 (53%) 9 (47%)
50–60 5 (26%) 6 (32%)
Prior surgery
Whipple 5 (26%) 4 (21%)
Palliative bypass 4 (21%) 6 (32%)
Stent 5 (26%) 5 (26%)
None 5 (26%) 4 (21%)
Response to first-line chemotherapy
a
PR 2 (11%) 3 (16%)
SD 9 (47%) 8 (42%)
PD 8 (42%) 8 (42%)
Sites of metastases
Abdominal mass 15 (79%) 16 (84%)
Liver 14 (74%) 12 (63%)
Lung 5 (26%) 4 (21%)
Spleen 1 (5%) 2 (11%)
Adrenals 1 (5%) 1 (5%)
Soft tissue 2 (11%) 3 (16%)
Histological grading
1 2 (11%) 1 (5%)
2 10 (53%) 12 (63%)
3 7 (37%) 6 (32%)
aAll patients had received palliative first-line treatment with bimonthly high-dose
gemcitabine. PR=partial remission, SD=stable disease, PD=progressive disease.
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Figure 1 Overall survival.
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patients suffering from pain at study entry, and in three out of 12
of those in the combination arm, pain intensity and/or analgesic
consumption was reduced as compared to baseline values. Three
patients (arm A) vs five (arm B) were classified as stable in this
category. Improvement in pain was accompanied by an improve-
ment in performance status in the patient in the raltitrexed arm,
and in two cases in the combination arm. One patient each in the
latter arm experienced an improvement in pain without worsening
of the performance status or had an improvement in performance
status while being rated stable in the pain category. With regard to
weight gain, the secondary measure of clinical benefit, there was no
patient in either treatment group who had a positive change (47%
increase from baseline). Accordingly, the total number of primarily
symptomatic patients experiencing a clinical benefit response was
1 (8%) vs 4 (29%) in favour of the combination arm. The median
duration to achieve a clinical benefit response was 5 weeks, and its
(median) duration was 14 and 17 weeks (range, 12–28 weeks) for
raltitrexed-treated and raltitrexed+irinotecan-treated patients,
respectively.
Toxicity
In both treatment arms, toxicity was recorded in all 19 patients. In
the raltitrexed arm, a median of three courses was given (range, 2–
6; 69 courses were analysed), and in the raltitrexed combination
arm, patients received a median of four courses (range, 1–6; 83
courses were analysed). Side effects associated with treatment are
listed in Table 2. Overall, data suggest that both chemotherapeutic
drug regimens were fairly well tolerated throughout the study. The
most frequently encountered toxicity was myelosuppression,
although grade 3/4 leukocytopenia/neutropenia occurred in only
four and five patients in arms A and B, respectively. Only two
treatment-related minor infections were noted in either group, and
grade 3 or 4 thrombocytopenia was not observed. As listed in
Table 2, also drug-related symptomatic toxicity was generally mild
in both the treatment groups. Gastrointestinal (GI) symptoms,
specifically nausea/emesis (42 vs 68%) and diarrhoea (42 vs 63%)
tended to be more frequently observed in the combination arm,
although symptoms were severe in only three patients in both
groups. The only additional adverse reactions that were more
commonly noted in the combination arm were partial alopecia (0
vs 42%), and cholinergic syndrome (0 vs 21%). Other symptomatic
toxicities were equally distributed between the two treatment
groups.
In the raltitrexed arm, no patient had a treatment delay, whereas
in the raltitrexed+irinotecan combination arm, treatment delays
were required in four patients because of intercurrent GI bleeding
(n¼l), biliary stent occlusion (n¼1), and personal reasons
(n¼2). Dose reductions for adverse reactions according to the
study protocol were effected in three patients in the raltitrexed
group (for emesis grade 3, and diarrhoea grade 37leukocytopenia/
neutropenia grade 4), and in three cases in the combination group
(also for grade 3 GI symptoms7grade 4 haematotoxicity in one).
Adverse reactions led to treatment discontinuation in only one
patient in the latter group because of continuing nausea/emesis
despite dose adjustment.
DISCUSSION
Owing to the lack of an active anticancer treatment regimen for
advanced pancreatic adenocarcinoma, the urgent need for such
therapy, and since preclinical data and the results of (meanwhile)
two published phase I investigations suggest an encouraging,
potentially synergistic activity between raltitrexed and irinotecan
(Aschele et al, 1998; Ford et al, 2000; Stevenson et al, 2001), the
present randomised phase II study was initiated in patients after
gemcitabine failure.
For the combination regimen, feasibility, an encouraging
antitumour effectiveness, and a fairly good tolerance were
demonstrated. With an IRC-confirmed objective response rate of
16% (a PR was noted in three out of 19 evaluable patients), it was
clearly superior to the comparator/control arm with raltitrexed
alone, in which no response was obtained. With an additional 32%
of patients experiencing SD in the raltitrexed+irinotecan arm (for
a median duration of 5 months), this second-line combination
regimen resulted in abrogation of progression of this aggressive
tumour in about half of our patients. Also the secondary study end
points of this trial, median PFS (4.0 months) and OS (6.5 months)
seem encouraging. Furthermore, almost one-third of our patients
with symptomatic disease (29%) experienced clinically significant
Table 2 Summary of maximum treatment-associated toxicities
Number of patients/World Health Organisation toxicity grade (%)
Raltitrexed Raltitrexed+irinotecan
Toxicity 1 2 3 4 1 2 3 4
Haematological and other laboratory-based toxicity
Leukocytopenia 5 (26.3) 2 (10.5) 3 (15.8) 1 (5.3) 6 (31.5) 3 (15.8) 4 (21.0) 1 (5.3)
Neutropenia 3 (15.8) 4 (21.0) 2 (10.5) 1 (5.3) 4 (21.0) 3 (15.8) 3 (15.8) 1 (5.3)
Thrombocytopenia 1 (5.3) FF F 2 (10.5) 1 (5.3) FF
Anaemia 7 (36.8) 7 (36.8) FF 5 (26.3) 6 (31.5) FF
Transaminases 6 (31.5) 3 (15.8) 1 (5.3) F 4 (21.0) 2 (10.5) 1 (5.3) F
Symptomatic toxicity
Nausea/vomiting 3 (15.8) 4 (21.0) 1 (5.3) F 3 (15.8) 9 (47.4) 1 (5.3) F
Stomatitis 1 (5.3) 1 (5.3) FF 2 (10.5) 1 (5.3) FF
Diarrhoea 4 (21.0) 2 (10.5) 2 (10.5) F 4 (21.0) 6 (31.5) 2 (10.5) F
Cholinergic syndrome FFF F 4 (21.0) FF F
Infection 1 (5.3) 1 (5.3) FF 1 (5.3) 1 (5.3) FF
Alopecia FFF F 3 (15.8) 5 (26.3) FF
Fatigue 5 (26.3) 2 (10.5) FF 5 (26.3) 3 (15.8) FF
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land sustained improvements in pain, analgesic consumption and/
or Karnofsky performance score. These objective and subjective
beneficial effects of raltitrexed+irinotecan were not negated by
frequent or severe, clinically relevant treatment-related toxicities.
Neutropenia, GI symptoms, asthenia, and transaminitis were
commonly noted; however, grade 3 adverse events requiring dose
adjustments occurred in only three patients, and there was no
treatment-related death.
Comparable therapeutic results in gemcitabine-pretreated pa-
tients with advanced pancreatic adenocarcinoma have only
occasionally been reported in the past, that is, in a pilot phase II
study of irinotecan (Klapdor and Fenner, 2000) and for a rather
complex combination regimen consisting of irinotecan, gemcita-
bine, 5-FU, leucovorin, and cisplatin (Kozuch et al, 2001). Other
chemotherapeutic drugs, such as paclitaxel (Oettle et al, 2000),
rubitecan (Stehlin et al, 1999), and irofulven (Weitman et al, 2001),
a unique cytotoxic agent that is related to the mushroom-derived
illudins, unfortunately, are only marginally effective or do not
seem to hold their promise (D Von Hoff, personal communica-
tions).
In conclusion, our data suggest that combined raltitrexed+ir-
inotecan seems to represent an effective salvage regimen in
patients with gemcitabine-pretreated metastatic pancreatic adeno-
carcinoma. In this randomised pick the winner study, we were able
to demonstrate a clear superiority compared to the raltitrexed
control arm. The choice of the latter drug might be criticised
because of the modest activity of the specific thymidilate synthase
inhibitor in this disease, even in the front-line setting (Pazdur et al,
1996). Based on the results of the two largest, recently published
phase III trials with a first-line FU (i.v. short term or protracted
venous infusion) arm (Burris et al, 1997; Maisey et al, 2002);
however, alternative use of this antimetabolite (resulting in a
response rate of 0–8%, PFS of 1–2.8 months, and OS of 4.4–5.1
months) would probably not have been a better choice and thus
have resulted in a different study outcome.
The activity, tolerability, and ease of administration noted in
this and other previously reported studies (Ford et al, 2000;
Stevenson et al, 2001), suggest that future trials of irinotecan and
raltitrexed in GI cancer patients are warranted. This should
certainly include pancreatic cancer, a disease where there is a dire
need to improve our therapeutic armentarium, in the front-line as
well as in the second-line treatment setting.
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